SCHEMBL6486106

SCHEMBL6486106

CC1CN(Cc2ccccc2)CCC1(C)c1cccc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.79
OPRD1 P41143 6/20 0.79
OPRK1 P41145 4/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656032 1.00 OPRM1 (0.79) OPRM1OPRD1OPRK1
SCHEMBL3833917 0.88 OPRM1 (1.00) OPRM1OPRD1OPRK1
SCHEMBL3833915 0.88 OPRM1 (1.00) OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL9262601 0.87 OPRM1 (0.98) OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL11453741 0.87 OPRM1 (0.98) OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL11453738 0.87 OPRM1 (0.98) OPRM1OPRD1OPRK1
SCHEMBL11401193 0.87 OPRM1 (0.69) OPRM1OPRD1OPRK1
SCHEMBL12168479 0.86 OPRM1 (1.00) OPRM1OPRD1OPRK1
SCHEMBL8351457 0.86 OPRM1 (1.00) OPRM1OPRD1OPRK1
SCHEMBL8351460 0.86 OPRM1 (1.00) OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085456-A1 Compounds useful in therapy PFIZER, INC. (US) 2005-04-21 US disclosed
US-6812236-B2 FOR THERAPY OF PRUTIUS PFIZER INC. 2004-11-02 US disclosed
EP-1072601-B1 4-arylpiperidine derivatives for the treatment of pruritus PFIZER (US) 2004-09-08 EP disclosed
EP-1077940-B1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER (US) 2004-07-14 EP disclosed
US-6750231-B2 SKIN DISORDERS; GASTROINTESTINAL DISORDERS PFIZER INC 2004-06-15 US disclosed
US-6610711-B2 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-08-26 US disclosed
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-04-24 US disclosed
US-20030004340-A1 New 4-arylpiperidine derivatives for the treatment of pruritus GIBSON STEPHEN PAUL (GB) 2003-01-02 US disclosed
US-6441000-B1 DISEASES MEDIATED BY OPIATE RECEPTORS PFIZER INC 2002-08-27 US disclosed
US-20020099216-A1 Compounds useful in therapy PFIZER INC. 2002-07-25 US disclosed
EP-1072592-A2 4-arylpiperidine derivatives for the treatment of pruritus PFIZER INC. (US) 2001-01-31 EP disclosed
EP-1072601-A2 4-arylpiperidine derivatives for the treatment of pruritus PFIZER INC. (US) 2001-01-31 EP disclosed
EP-1055668-A1 New 4-arylpiperidine derivatives for the treatment of pruritus PFIZER INC. (US) 2000-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085456-A1 Compounds useful in therapy OPRL1, OPRD1, BDKRB1 OPRM1 5/4885OPRD1 2/4885OPRK1 9/4885
US-20030004340-A1 New 4-arylpiperidine derivatives for the treatment of pruritus HRH2, HRH4, HRH1 OPRM1 9/4885OPRD1 4/4885OPRK1 11/4885
US-20020099216-A1 Compounds useful in therapy OPRD1, OPRL1, OPRM1 OPRM1 3/4885OPRD1 1/4885OPRK1 4/4885
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses HRH2, HRH4, HRH1 OPRM1 409/4885OPRD1 102/4885OPRK1 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.